

## Index

### a

- absorption-based imaging techniques 443
- acne pathogenesis and comedolysis
  - mouse models 122
- acoustic cavitation 275–276
- acoustic impedance (Z) 311, 317
- acoustic oscillation 310
- acoustic radiation force 275, 328
- acoustic radiation force impulse (ARFI) 328
- acoustic stack 314, 319
- acoustic waves 271–272, 274–276, 412, 429
- acoustic-lens-based photoacoustic imaging 413
- acoustic-resolution PAM (AR-PAM) 413, 418, 420, 424
- acquired reticulated hyperpigmentation, of neck 41
- acral lentiginous melanoma (ALM) 93
- acral vitiligo, of feet 50
- actinic keratoses (AKs) 88, 90
- acute cutaneous lupus erythematosus (ACLE) 47, 48
- adipose tissue-derived stromal cells 19
- adipose-derived mesenchymal stem cells 162
- adipose-derived microvascular fragments (ad-MVFs) 420
- AdminStamp<sup>®</sup> device 243
- albumin 424–425
- AlloDerm 157–158
- allografts 157
- alopecia areata (AA) 42, 127
  - mouse and rat models of 121–122
- 5-aminolevulinic acid (ALA) 214, 226, 247
- amphiphilic polymers 154, 188
- ampicillin trihydrate loaded chitosan nanoparticles 186
- angiogenesis 17, 115, 120, 161–162, 414, 418–420, 425
- anionic surfactants 180, 181
- anisotropic wet etching 233
- anodal iontophoresis 297, 303
- anti-integrin  $\alpha_v\beta_6$  antibody 417
- anti-tetanus toxoid IgG 283
- antigen presenting cells (APCs) 235, 283
- Apligraf 111, 158, 159, 160
- apocrine gland 8–9
- apparent diffusion coefficient (ADC) 350, 375
- appendageal diffusion 171
- aprotinin 298
- Aranz Silhouette 22
- array ultrasound transducers 318–320, 326–329
- arterio-venous anastomoses (AVAs) 453, 454
- arthritis mutilans 38
- atopic dermatitis (AD)
  - clinical features 41–42
  - corticosteroid creams 43
  - crisaborole 43
  - definition 40–41
  - diagnosis 42–43
  - dog models of 126

- atopic dermatitis (AD) (*contd.*)  
 genetic risk factors 42  
 inflammatory cascades 42  
 lesional and non-lesional skin tissues  
 41–42  
 prevalence 40–41  
 pruritus 41  
 risk factor 42  
 treatment 43
- attenuation 275, 276, 310, 317, 318,  
 325–326, 341, 352, 353, 355,  
 379–381, 420
- atypical protein kinase C iota/lambda  
 (aPKC) 86, 88
- auto-correlation transport equation  
 449–451
- auto-fluorescence (AF) 372
- autoantibodies 36, 46, 48, 50–51,  
 61–64, 66–69, 72, 74, 121–122
- autoimmune blistering diseases 61–74  
 dermatitis herpetiformis 70–72  
 epidermolysis bullosa acquisita  
 72–73  
 pemphigoid 68–70  
 pemphigus 62–67
- autoimmune bullous dermatoses  
 (AIBDs), mouse models of  
 120–121, 128
- autoimmune diseases of skin 36–51  
 atopic dermatitis 40–43  
 cutaneous lupus erythematosus  
 47–49  
 dermatomyositis 45–47  
 generalized vitiligo 49–51  
 psoriasis 36–40  
 scleroderma 43–45
- autoimmune disorders 35–51, 121  
 dog models of 127
- autoinflammation 36
- autologous skin grafts 157
- avalanche photodiode (APD) 450
- azathioprine 45, 47, 67, 70, 73
- b**
- B cell-activating factor (BAFF) 46
- B-mode ultrasound imaging 310, 321
- B/D-scan (brightness/depth) concept  
 322, 323
- Bacille Calmette–Guérin (BCG) 207
- backing layer 314, 317–320
- basal cell carcinomas (BCCs) 83–88,  
 417  
 cell of origin 85–86  
 chemotherapy 88  
 classification 85  
 loss of *Ptch1* 86  
 Mohs surgery 87  
 photodynamic therapy 87  
 radiotherapy 87  
 risk factors 84  
 signaling pathways 86–87  
 SMO inhibitors 84  
 staging 85  
 surgical excision 87
- basement membrane (BM) 2, 4, 5, 19,  
 62, 69, 111, 114, 371
- beamforming 324, 326–327
- bioactivated polypyrrole 149
- biodegradable synthetic polymers  
 chitosan nanoparticles 186  
 gelatin nanoparticles 186  
 PLGA copolymers 187  
 poly- $\epsilon$ -caprolactone 187–188  
 polytyrosine 188
- Biojector B2000 211
- bleomycin, intralesional needle-free jet  
 injections of 214
- blood circulation monitoring 443
- blood flow 248, 417, 418, 421, 424,  
 443–445, 449–457, 459–460
- blood flow index (BFI) 450, 451,  
 454–455, 457
- blood flow velocity 421
- bone marrow derived fibroblasts 19
- bone marrow derived mesenchymal  
 stem cells 161, 162
- BRAF inhibitor-treated melanomas  
 95
- Brownian motion model 449
- bullous dermatoses 61, 68, 73, 115, 128  
 fruit fly models of 115
- bullous pemphigoid (BP) 66, 68,  
 105–106, 121

- burn injury assessment and monitoring  
of healing 423, 424
- burn wounds 21, 120, 123, 129
- C**
- Caenorhabditis elegans* 112–113
- caffeine 178, 230, 238, 279, 281
- calcitonin 298–299
- canine atopic dermatitis 126
- Canis lupus familiaris* 126–128
- CARD11* gene 42
- CARD14 peptides 38
- cationic hybrid polymeric nanoparticles,  
for nucleic acid delivery 188
- cationic surfactants 180–181
- Cavia porcellus* 122–124
- cellular-level structure imaging 372
- cemiplimab 91
- ceramic microneedle fabrication 233
- chemical enhancers 172–182, 300
- alcohols, fatty alcohols and glycols  
175
- amides/azones and derivatives  
175–176
- characteristics 173
- cyclodextrins 182, 183
- definition 172
- dimethyl sulfoxide 177
- essential oils 179–180
- esters 176–177
- fatty acids 178–179
- phospholipids 182
- pyrrolidones 181–182
- surfactants 180–181
- terpenes 179–180
- terpenoids 179–180
- ureas 177–178
- water 173–174
- chemical shift spectroscopic acquisition  
method 349–350
- chloramphenicol (CAM)-loaded  
polycaprolactone (PCL) fiber  
mats 188
- cholecalciferol nanosuspension  
246–247
- chronic cutaneous lupus erythematosus  
(CCLE) 47, 48
- chronic diabetic wound healing model  
19
- circular flat transducers 273
- circulating bone marrow derived cells  
19
- circulating tumor cells (CTCs) detection  
416–417
- clinical magnetic resonance imaging  
challenges for high-resolution MR  
imaging 342–345
- optimized RF coil design 345–348
- skin on the face 349–350
- state-of-the-art of 348–349
- water states in skin 350, 351
- clinical microdialysis (CM) 238
- clobetasol-17-propionate (CP)  
encapsulated chitosan/lecithin  
nanoparticles 186
- coat and poke approach, for transdermal  
drug delivery 226
- coated microneedles 226
- cold-induced vasodilation (CIVD)  
451–455
- collagen coated biodegradable PCL  
nanofibrous scaffold 154
- collagen fibres 6, 111, 152, 371
- collagen-glycosaminoglycan matrix  
(CGM) 160
- color-coded tissue elastography 330
- coloured dyes 240
- commercial HD-OCT systems 387
- commercial insulin formulations 208
- concave polyvinylidene fluoride  
transducer 324
- confocal laser scanning microscopy  
(CLSM) 372, 384
- in microneedles 240
- confocal microscopy (CM) 24, 341
- conventional B-mode imaging 324
- Cool.Click™ 210
- Cool.Click 2 needle-free injection device  
210
- corneocyte bricks 10
- corneocytes 6, 9, 10–11, 110, 126, 170,  
172, 174
- corneodesmosomes 11–12

- correlation diffusion equation (CDE) 459
  - correlation transfer equation (CTE) 459
  - corticosteroids 21
    - dermatomyositis treatment 47
    - pemphigoid 70
    - pemphigus 67
  - CREST syndrome 43, 45
  - crisaborole 43
  - curcumin loaded MePEG-PCL nanoparticles 188
  - curcumin-loaded liposome-siRNA complex 303
  - curcumin-loaded nanoparticles (CUR-NPs) 186
  - Cutaneous Lupus Area and Severity Index (CLASI) 48
  - cutaneous lupus erythematosus (CLE)
    - antibody testing 49
    - autoimmune pathology 48
    - clinical features 47–48
    - clinical symptoms 47
    - definition 47
    - diagnosis 48–49
    - environmental factors 48
    - subtypes 47
    - treatment 49
  - cutaneous squamous cell carcinoma (cSCC) 88, 417
    - cell of origin 90
    - cemiplimab 91
    - classification 89–90
    - electrodesiccation and curettage 91
    - HPV vaccines 91
    - Mohs surgery 91
    - radiotherapy 91
    - risk factors 89
    - signaling pathways 90
    - staging 90
    - stratified epithelial cells 90
    - surgical excision 91
  - cutaneous wound healing, *ex vivo*
    - models of 107
  - cyclic urea analogues 178
  - cyclodextrins 182, 183
  - cyclosporine 40, 47
    - inflammatory EBA 73
  - cystic fibrosis (CF) 292–293
- d**
- Danio rerio* 116–118
  - danipletim (DP) 302
  - dapsone 49, 67, 70, 71–72, 73
  - de-scumming 233
  - deep burns (DBs) 424
  - deep dermal burns (DDBs) 424
  - deep tissue blood flow and cold-induced vasodilation 451, 452
  - deoxy-hemoglobin (HbR) 411, 415
  - Dermagraft 158
  - dermal fibroblast 6–7, 8, 20, 109, 111, 149, 154, 157, 158–159, 161
  - dermal papilla 2, 3, 7, 8, 71, 161, 248, 384
  - DermaRoller® 243, 248
  - dermatitis herpetiformis (DH) 62, 70–71
  - dermatomyositis (DM)
    - clinical sign 46
    - definition 45–46
    - diagnosis 46–47
    - histopathologic findings 46
    - incidence 45
    - malignancy screening 46
    - myositis-specific autoantibodies 46
    - prevalence 45–46
    - skin manifestations 46
    - symptoms 46
    - therapy 47
  - dermatophytosis 123
  - dermis 2, 6–7, 111, 170, 171
  - dexamethasone sodium phosphate (DEX-P) 297
  - Diclofenac potassium (DP) 301
  - diffractive scattering 312
  - diffuse correlation spectroscopy (DCS) 443, 449–451
  - diffuse near-infrared spectroscopy (DNIRS) 23
  - diffuse optical tomography (DOT) 458, 459
  - diffuse speckle contrast analysis

- deep tissue blood flow and cold-induced vasodilation 451–456
  - and imaging, future of 459–460
  - theory of 449–451
- diffuse speckle tomography
  - depth sensitivity of flow measurement 456–458
  - tomographic flow imaging 458–459
- digital beamformer 326
- digital-to-analog converter (DAC) 327
- dimethyl sulfoxide (DMSO) 177, 300
- dimethylformamide (DMF) 177, 300
- direct current (d.c) electric pulse 300
- discoïd lupus 47, 48
- dispersion 204, 209, 215, 353, 359, 376–378
- disposable cartridge jet injectors (DCJIs) 202, 203
- dissolving microneedles 228
  - solvent casting fabrication method 234
  - vaccine delivery 237
- dogs
  - atopic dermatitis 126–127
  - bullous dermatoses 128
  - follicular hyperkeratosis and keratolysis 127
  - local and systemic autoimmune disorders 127
  - skin anatomy and physiology 126
- domestic pig model
  - cutaneous permeability 129
  - cutaneous wound healing 129
  - skin anatomy and physiology 128
- Donnan exclusion effect 184
- Draize test 125
- Drosophila melanogaster* 113–116
- drug dosage medium 279–280, 282
- drug formulations 225, 277, 279–282, 304
- drug sonophoresis 282
- drug-induced pemphigus 63, 66–67
- dual-wavelength imaging 415
- dual-wavelength PAM 415
- Duhring's disease 62, 70
- dummy fingerprint 397, 398
- dupilumab 43
- e**
- eccrine gland 8–9, 119
- effective reflection coefficient 449
- elastin 2, 6–7, 25–26, 247, 342
- elastographic ultrasound imaging techniques 328
- elastography method 359
- electroporation and microneedles 245
- electrospinning method 149, 153–157, 161, 163
- electrospun PCL nanofiber 152
- embryonic stem cells (ESCs) 162
- endogenous biomolecules 412
- en face* fingerprint images 394–396
- EpiDerm™ 110–111
- epidermal desmosomal adhesion complex 62
- epidermal growth factor receptor (EGFR) inhibitors 91
- epidermal homeostasis 159
- epidermal transglutaminase (eTG) 71
- epidermis 2, 170, 371
  - description 3–4
  - stratum basale 5
  - stratum corneum 6
  - stratum granulosum 6
  - stratum lucidum 6
  - stratum spinosum 5
- epidermodysplasia verruciformis (EV) 89
- epidermolysis bullosa acquisita (EBA) 62, 72–73
- Episkin® 111
- essential oils (EOs) 179–180
- estradiol (E2)-loaded PLGA nanoparticles 304
- etching process 233
- ethanol 149, 175
- excision biopsy 371
- exit jet power 204
- ex vivo* human skin models
  - advantage 107
  - cutaneous wound healing 107–108
  - disadvantages 107

- ex vivo* human skin models (*contd.*)
  - hair follicle culture 108
  - skin barrier function and dermal absorption 107
- Eykonya Wound Measurement System 22
- f**
  - Fabry–Perot transducer 420
  - Fabry–Perot ultrasound sensors 428
  - Face, Legs, Activity, Cry and Consolability (FLACC) tool 213
  - fatty acid esters 176
  - fatty acids 9, 11, 178–179, 182, 184, 190, 300
  - fibronectin 111, 148, 149–152, 163
  - field-programmable gate array (FPGA) 327, 426
  - fingerprint recognition 392, 394
  - fixed focus 321, 326
  - FLG* gene 42
  - flufenamic acid-loaded PLGA nanoparticles 189
  - fluid-filled blisters 69
  - fluorescein isothiocyanate (FITC)-dextrans 303
  - fluorescence lifetime imaging (FLIM) 372
  - fluorescence mapping 342
  - 5-fluorouracil (5-FU)
    - antitumor activity 247
    - BCC treatment 88
  - focused ultrasound transducer 318
  - Fogo Selvagem (FS) 64
  - forensic subsurface fingerprint detection 392, 394
  - Fourier domain mode locked (FDML) laser source 375
  - Fourier-domain (FD) optical coherence tomography (OCT)
    - FF-OCT 375, 376
    - micro-OCT 376–381
  - fruit fly
    - bullous dermatoses, models of 115
    - cutaneous innate immunity 115
    - cutaneous wound healing 114–115
    - epidermis, anatomy and physiology of 114
    - skin cancer, models of 115–116
  - full field (FF)-OCT 375, 376
- g**
  - $\beta$ -galactocerebrosidase (GALC) 69
  - gas-powered needle-free jet injector 211
  - gelatin modified PLGA nanofibers 153
  - gelatin nanoparticles 186
  - generalized vitiligo (GV)
    - autoimmune pathophysiology 50
    - calcineurin inhibitors 51
    - characteristic feature 49
    - clinical sign 49–50
    - definition 49
    - diagnosis 50–51
    - melanocyte destruction 50
    - topical corticosteroids 51
  - genodermatoses 118
    - rabbit models of 126
  - genome-wide association studies (GWAS) 38, 42, 44, 48, 50, 69
  - geranial 301
  - Gibson Cooke (GC) technique 293
  - glass microneedle fabrication 233
  - glucose level monitoring 425
  - glucose monitoring 293
  - GlucoWatch<sup>®</sup> 293
  - gluten-free diet 71
  - glycosaminoglycans 7
  - gold nanoparticle-labeled
    - adipose-derived stem cells (ASCs) 425
  - good manufacturing practice (GMP) 250–251
    - microneedle evaluation 250
  - Gottron's papules 46
  - granisetron (GST) 231, 297
  - granuloma annulare 213
  - ground substance, composition of 7
  - guinea pigs
    - advantages 122
    - burn wounds study 123–124
    - dermatophytosis study 123

- epidermal permeability topical
  - irritant testing 123
  - pigmentation studies 124
  - skin anatomy and physiology 123
- gyromagnetic ratio 343
- h**
- hair follicle 8
  - bioengineering 161
  - culture 108
- hand-held multiphoton imaging
  - technology 25
- herpes gestationis 69
- high-definition (HD)-OCT 374, 375
- high-frequency annular array transducer
  - based imaging systems 327
- high-resolution MR imaging 342, 343
- high-resolution OCT (HR-OCT)
  - systems 372, 373–398, 399, 411
- high-temperature superconducting (HTS) material 346–348
- histology 21, 25, 48, 117, 119, 129, 323, 371, 374, 382, 388, 400, 423, 427
- hollow microneedles 227
- HPV vaccines 91
- human growth hormone (hGH) 210
- human leukocyte antigen (HLA) class II alleles 63
- human skin structure 170, 171
- hyaluronic acid (HA) 111, 149–150, 214–215, 247–248
- hydrogel-forming microneedles 230, 234, 238
- hyperglycemia 209–210
- hyperhidrosis 292
- hyperspectral imaging 22, 23
- hypertrophic scars 21, 25, 108, 111, 125, 214
- hypodermic needles 203, 211, 224, 238, 241, 249, 250
- hypodermis 2–3, 7, 9, 116, 117, 119, 126, 170, 342, 347–348, 371
- i**
- IgA pemphigus 63, 66
- imiquimod
  - BCC treatment 88
  - induced psoriasis model 120
- immune system
  - adaptive arm 35
  - function of 35
  - innate arm 35
- immunisation 283–284
- immunologic net 283
- infiltrative (morpheaform) BCCs 85
- inflammatory form, of EBA 72
- insulin 190, 191, 208–210, 225, 228–230, 242, 245, 278–279, 281, 297, 300, 303, 425
- intensity reflection coefficient ( $R_i$ ) 311
- intercellular lipids 6, 10–11, 181
- in vitro* human skin models 108–112
  - three-dimensional reconstructed models 110–112
  - two-dimensional cell culture models 109
- in vivo* animal models
  - C. elegans* 112–116
  - C. porcellus* 122–124
  - Canis lupus familiaris* 126–128
  - D. melanogaster* 113–116
  - D. rerio* 116–118
  - M. musculus* 118–122
  - O. cuniculus* 124–126
  - Sus scrofa* domesticus 128–129
- iontophoresis
  - with chemical enhancers 300–302
  - clinical and preclinical studies 293, 295, 296
  - cystic fibrosis 292–293
  - delivery of anesthetics for pain management 292
  - glucose monitoring 293
  - hyperhidrosis 292
  - macromolecules 297–300
  - with microneedles 245, 302–303
  - nanoparticles 303–304
  - publications 293–294
  - small molecules 297
- iontophoretic efficiency enhancers (IEE) 301, 323–324, 329, 395–398
- ipilimumab 95
- iris recognition 392

isopropyl myristate 177  
isotropic wet etching 233

**j**

J-Tip™ 212, 213

**k**

keloid scars 15, 18, 21  
keratin filaments 4, 6, 11  
keratinization 6, 37  
keratinocyte stem cells 159  
keratinocytes 2, 4–6, 9, 18–19, 25,  
37–39, 42, 62, 87–90, 109–112,  
114, 117, 119, 128, 147, 159–160,  
162, 170, 204, 283, 355  
keratohyalin granules 6  
ketoprofen (KT) 187, 246, 297  
ketoprofen choline chloride (KCC)  
297

**l**

Langerhans cells 4, 5, 35, 119,  
235–236, 283  
laser Doppler flowmetry (LDF) 443,  
453  
laser speckle contrast imaging (LSCI)  
444–447  
    applications 446–447  
    working principle of 444–446  
lauric acid 178, 179  
lead Zirconate Titanate [Pb(Zr, Ti)O<sub>3</sub> or  
PZT] 314  
lens focused single-element transducers  
318  
lens focused ultrasound transducer  
318  
lentigo maligna melanoma (LMM) 93  
leukocytes 16–18, 39, 44, 63–64, 117  
leukotrichia 51  
leuprolide 245, 298  
lidocaine jet injection 212  
light-emitting diodes (LED) 429  
limited cutaneous systemic scleroderma  
43  
limited-angle reflection tomography  
324  
linear alcohols 175

linear array ultrasound transducer  
320, 326  
linear propagation of ultrasound 274  
linear scanning 322  
lipid-polymer hybrid nanoparticle  
system 188  
lipofundin 457  
liposomes 303  
liquid jet injectors 201, 209  
lithium niobate (LiNbO<sub>3</sub>) 316  
lithium tantalite (LiTaO<sub>3</sub>) 316  
local anesthetics 212–213  
localised transport regions (LTR) 278  
low-frequency oscillation (LFO) analysis  
459  
lucidum keratinocytes 6

**m**

Mach-Zehnder interferometer 375  
Macroflux® 243, 244  
macromolecules 129, 153, 170, 189,  
191, 206, 215, 224, 226, 297–300,  
302, 349, 353  
magnetic resonance imaging (MRI)  
46, 334, 341–359, 450, 451  
magnetization transfer (MT) 353–355,  
358  
mannitol 181, 281  
Mantoux injection 207  
matching layer 272, 317  
matrix metalloprotease 9 (MMP9) 19  
McGill Pain questionnaire 242  
mechanical scanning 321, 326–327  
Medi-Jector Vision® 210  
Meissner corpuscles 3, 7  
melanin 5, 23, 26, 50, 117, 342, 411,  
414–417, 421, 422, 426–428, 443  
melanocytes 4, 5, 39, 49–50, 92, 94,  
117, 119, 124, 417  
melanoma  
    BRAF inhibitors 95  
    cell of origin 94  
    *D. rerio* models 117  
    death rates 92  
    dog models of 127  
    electrochemotherapy 95  
    interferon alpha-2b 95



- ipilimumab 95
  - using mouse models 121
  - nonsurgical methods 95
  - risk factors 92
  - signaling pathways 94
  - surgical excision 94–95
- melanoma detection and diagnosis 414, 415
- melanoma thickness imaging 415
- 1-menthol 301
- Merkel cells 4–5, 86
- mesoporous silica nanoparticles (MSNs) 303
- metabolic rate of oxygen 421
- metal microneedle fabrication 233
- metastatic BCCs 85, 88
- methotrexate 40, 45, 47, 49, 67, 73, 211–212, 245
- methylene blue 230, 240
- metoclopramide (MCL) 297
- 100 MHz single-element ultrasound transducer 322
- 100 MHz ultrasound malignant melanoma 323
- Michelson interferometer based TD-OCT 373
- micro-OCT 376–381
- microbubbles 276, 282, 429
- MicroCor<sup>®</sup> 243
- micromoulding-based methods 234
- microneedles (MNs) 223, 302, 388
  - alopecia treatment 248
  - assisted microparticle and nanoparticle permeation 245–247
  - benefits 224
  - biomarker extraction in animal models 238
  - coated 226–227
  - cost 250
  - dissolving 228–230
    - and electroporation 245
  - fabrication methods 232–235
  - future considerations 249–250
  - hair pathology 248
  - height of 224
  - hollow 227–228
  - hydrogel-forming 230–231
  - invasive and pain-free characteristics 224
  - and iontophoresis 245
  - microbial contamination 249
  - micropore closure 241, 242
  - patient drug monitoring 237–239
  - safety considerations 249
  - skin disorder management 247–248
  - skin insertion
    - pain perception 242–243
    - and recovery process 239–242
    - skin irritation 243
  - skin scar treatment 248
  - solid 225, 226
  - and sonophoresis 245
  - and vaccine delivery 235–237
  - wet etching 233
- MicronJet<sup>™</sup> 243, 244
- micronodular BCCs 85
- microscopy coils 345
- microvessel density (MVD) 420
- Mie scattering 312
- Mobile Wound Analyzer 22
- monocyte chemoattractant protein 1 (MCP-1) 18
- morpholino oligonucleotides 118
- mouse models
  - acne pathogenesis and comedolysis 122
  - alopecia areata 121–122
  - autoimmune bullous dermatoses 120–121
  - cutaneous wound healing study 120
  - melanoma study 121
  - of psoriasis 120
- MR microscopy 351
- mucosal melanoma (MM), dog models of 127
- mucous membrane pemphigoid (MMP) 19–20, 68–69, 72, 121
- multi-channel dynamic beamforming techniques 327
- multi-channel MR scanners 345
- multi-photon microscopy (MMP) 20, 68, 69, 72, 121, 372

- multidose nozzle jet injectors (MUNJIs) 202
- multimodality imaging 428, 429
- multiphoton imaging approach 24–27
- multiphoton microscopy (MPM) 24, 341, 342, 372
- multiple organ dysfunction syndrome (MODS) 424
- multiscale OCT system 388
- multispectral optoacoustic mesoscopy (MSOM) 421
- multispectral optoacoustic tomography (MSOT) 416
- murine skin anatomy and physiology 119
- Mus musculus* 118–122
- mycophenolate 45
- mycophenolate mofetil 67, 70
- myositis-specific autoantibodies (MSAs) 46
  
- n**
- nail bed psoriasis 38
- nailbed identification 392
- nanobubble stabilising nanoparticles 282
- nanofibers fabrication 154, 155
  - electrospinning method 156
  - phase separation 156
  - self-assembly 154
- nanofibrous gelatin/bioactive glass (NF-GEL/BG) composite hydrogel 152
- nanoparticles 153, 169–192, 241, 245–247, 277, 282, 303–304
  - transdermal delivery using 182
- nanostructured materials, for skin tissue engineering 148
  - collagen and chitosan 148–149, 150–151
  - fibronectin 149
  - hyaluronic acid 149, 152
  - natural and synthetic biodegradable nanofibers 153–154
  - natural biomaterials 148
  - synthetic polymers 152–153
- narrow-bore MR microscopes 351
- necrobiosis lipoidica 213
- needle-free immunization, advantages of 208
- needle-free liquid jet injectors
  - advantages 201
  - components and functioning principle 203
  - local drug delivery 212–215
  - for nano/microparticles 215–216
  - penetration depth, tunability of 204, 206
  - spring-powered 203
  - for systemic drug delivery 206
- needle-phobia 201
- negatively charged Diclofenac potassium (DP) 301
- neutralising antibody titres 283
- neutrophils 17–18, 35, 37, 39, 69, 71, 73, 129, 236
- NLR family pyrin domain containing 1 gene (*NLRP1*) 50
- nodular BCCs 85–87, 206, 331
- non-fibroblast cells 7
- non-inflammatory form, of EBA 72
- non-ionic surfactants 180–181
- non-specular scattering 311
- Non-TNF $\alpha$  inhibitor biologics 40
- nonlinear propagation of ultrasound 274
- nonsteroidal anti-inflammatory drugs (NSAIDs) 297
- normal skin imaging 382–386
- nuclear magnetic resonance (NMR) spectroscopy 351, 354, 355
- nucleic acids, delivery of 170
  
- o**
- octyl salicylate (OS) 176
- off-resonance saturation 355, 357
- oleic acid (OA) 178–179, 187, 301
- oligonucleotides 118, 190, 281
- on-site photoacoustic cytometry 416
- open-circuit *g* coefficient 315
- optical coherence tomography (OCT) 241, 341
  - based forensic subsurface fingerprint detection 392, 394

- Fourier-domain 376  
 in microneedles 240, 241  
*in situ* micro-needle real-time  
   swelling in skin 388, 390  
 normal skin imaging 382–386  
 polarization sensitive 381  
 skin imaging in clinical practice 387  
 time-domain 373  
 optical frequency domain imaging  
   (OFDI) 373  
 optical-resolution PAM (OR-PAM)  
   413, 418, 419, 421, 425, 428  
 oral pemphigus vulgaris 63  
 OrCel 159  
 organoids 112  
*Oryctolagus cuniculus* 124–126  
 Osteogenesis Imperfecta (OI) patients  
   353  
 ovalbumin 226, 231, 246, 283–284  
 oxazolidinone 300  
 oxy-hemoglobin (HbO<sub>2</sub>) 411, 415  
 oxygen saturation 22, 412, 417–421
- p**  
 Pacinian corpuscle 3, 7  
 papillary dermis 7, 8, 24, 25, 371–372,  
   382–384  
 paraneoplastic pemphigus (PNP) 63,  
   64, 66, 67  
 PCL/poly (ethylene oxide) (PEO) fiber  
   mats 188  
 pemphigoid  
   bullous pemphigoid 68  
   definition 68  
   diagnosis 70  
   ELISA tests 70  
   incidence 68  
   mucous membrane pemphigoid 69  
   pemphigoid gestationis 69–70  
   sub-epidermal blistering 68  
   treatment 70  
 pemphigoid gestationis (PG) 69–70  
 pemphigus  
   clinical hallmark 67  
   corticosteroids 67  
   definition 62  
   direct immunofluorescence 67  
   drug-induced 66–67  
   IgA 66  
   incidence 62–63  
   paraneoplastic pemphigus 64, 66  
   pemphigus erythematosus 66  
   pemphigus foliaceus 64  
   pemphigus vulgaris 63–64  
   treatment 67  
 peptide-nucleic acid nanoconjugates  
   190, 191  
 peptides, for skin permeation 190  
 phase separation 154–156, 163  
 phospholipids 11, 182, 184, 215  
 photoacoustic computed tomography  
   (PACT) 413  
 photoacoustic endoscopy (PAE) 414  
 photoacoustic flow cytometry  
   416–417  
 photoacoustic imaging (PAI) 429, 456  
 photoacoustic macroscopy (PAMac)  
   414  
 photoacoustic microscopy (PAM) 372,  
   413–415  
 photoacoustic tomography (PAT)  
   burn injury assessment and  
     monitoring of healing 423–425  
   circulating tumor cells detection  
     416–417  
   detection of non-cancerous skin  
     diseases 422–423  
   endogenous contrast agents 411  
   glucose level monitoring 425–426  
   imaging technology 412–414  
   melanoma detection and diagnosis  
     414–416  
   molecular applications 426–428  
   tumor environment analysis  
     418–421  
 photolithography 232–233  
 PictZar (BioVisual Technologies) 22  
 piezo-material-based transducers 428  
 piezoelectric materials 272  
   ceramics 316  
   piezoelectric single crystals 316  
   relaxor-based single crystals 316  
 piezoelectric single crystals 316  
 pigmented lesions 422

- pilocarpine 186, 245, 293  
 pilocarpine hydrochloride-loaded  
   gelatin nanoparticles 186  
 PLA microneedles 247  
 PLA porous membrane 152  
 plaque psoriasis 39  
 platelet derived growth factor (PDGF)  
   16–18  
 poke and flow approach, for transdermal  
   drug delivery 227  
 poke and patch approach, for  
   transdermal drug delivery 225  
 poke and release principle, for  
   transdermal drug delivery 228  
 polarization sensitive OCT 381  
 polarization-sensitive optical coherence  
   tomography (PS-OCT) 423  
 poly- $\epsilon$ -caprolactone (PCL) nanoparticle  
   187  
 poly(D, L-lactide-co-glycolide) (PLGA)  
   nanoparticle 153, 156, 163, 185,  
   187–188, 189, 234, 245–246,  
   303–304  
 poly(acrylic acid) microneedles 246  
 polycrystalline ferroelectric ceramic  
   materials 314  
 polystyrene-block-poly (acrylic acid)  
   (PS-*b*-PAA/PS) MNs 388  
 polytyrosine 188  
 polyvinyl chloride plastisol (PVCP)  
   428  
 port wine stain (PWS) 414, 422, 446,  
   447  
 press focused and lens focused  
   transducers 318  
 press focused single-element  
   transducers 318  
 pressure amplitude reflection coefficient  
   311  
 programmable and real-time  
   annular-array imaging platform  
   327  
 propylene glycol (PG) 301  
 propylene glycol monocaprylate  
   (PGMC) 176, 177  
 propylene glycol monolaurate (PGML)  
   177  
 protein-based drugs 297  
 prototype TD-OCT 374  
 pruritus 41, 72  
 psoriasis 422, 423  
   clinical features 37–39  
   clinical manifestation 37  
   definition 36–37  
   diagnosis 39–40  
   environmental factors 39  
   JAK/STAT signalling pathway 39  
   murine models of 120  
   prevalence 36–37  
   treatment 40  
 Psoriasis Area Severity Index (PASI)  
   422  
 psoriatic nail disease 38  
 pulse oximetry 420  
 pustular psoriasis 37, 39  
 pyrrolidones 175, 181–182  
 PZT ceramics 316
- q**
- quantitative MR imaging of the skin *in*  
   *vitro*  
   opportunities with preclinical MR  
   systems 351–352  
   skin of the calf 351  
   state-of-the-art of *in vitro* MR  
   applications 352–353  
   water state quantification in  
   reconstructed skin 354–359  
 quartz (SiO<sub>2</sub>) 233, 272, 316
- r**
- rabbits  
   acne venenata and contact dermatitis,  
   models of 125  
   cutaneous wound healing and  
   scarring 125  
   for genodermatoses study 126  
   skin anatomy and physiology  
   124–125  
 radiative transfer equation (RTE) 459  
 radio-frequency coils 345  
 radiotherapy 21, 87  
   cutaneous squamous cell carcinoma  
   91

- Raman microscopy (RM) 372  
 Raman vibrational spectroscopy  
     23–24  
 random flow model 449  
 Raster scanning 413  
 Rayleigh scattering 312  
 Raynaud's phenomenon 44–45, 447  
 reactive ion etching (RIE) 233  
 real-time compound ultrasound  
     imaging 332  
 reconstituted human dermis (RHD)  
     models 111  
 reconstituted human epidermis (RHE)  
     models 110–111  
 reconstituted skin equivalent (RSE)  
     model 111–112  
 reconstructed skin 110, 111, 354–359  
 red striae 41  
 reduced scattering coefficient 449  
 reflectance confocal microscopy (RCM)  
     24, 387  
 reflected echo signal 313  
 reflection 310–312, 317, 420, 429, 449  
 refraction 310–311  
 Regranex™ 17  
 relative dielectric constant 315  
 relaxor materials 316  
 relaxor-based single crystals 316  
 reticular dermis 7, 20–21, 24–25, 371  
 retinol 186  
 reverse iontophoresis (RI) 238, 293  
 RF coil design 345, 347  
 rituximab 45, 47, 49, 67, 70, 73–74  
 roundworm  
     cutaneous wound healing 113  
     epidermis, anatomy and physiology of  
         112
- S**  
 salmon calcitonin (sCT) 298  
 salt leaching electrospinning (SLE)  
     technique 47–49, 127, 161  
 sampling window duration 344  
 scattering 24–25, 310–312, 345, 372,  
     385, 389, 429, 444, 446, 448–449  
 scattering coefficient, reduced 449  
 scleroderma  
     causes 44  
     clinical features 44  
     curative therapy 45  
     definition 43  
     diagnosis 44–45  
     immunosuppressants 45  
     patient clinical examination 45  
     prevalence 44  
     signs and symptoms 44  
 scratch assay 109  
 sebaceous gland 2–3, 8, 10, 66, 86, 107,  
     112, 119, 122, 125, 159, 171–172,  
     348, 371  
 sebocytes, in vitro culture of 109  
 seborrheic keratosis 330, 333, 422  
 second harmonic generation (SHG)  
     25, 372  
 sector scanning 322–323  
 self-assembly 154–156, 163, 188  
 Senear–Usher syndrome 66  
 shear wave imaging 328  
 signal-to-noise ratio (SNR) 344–346,  
     348, 354, 375, 381, 429  
 silicon microneedle fabrication 232  
 silk fibroin (SF) nanofiber scaffold 161  
 single emulsion solvent evaporation  
     method 246  
 single-element piston ultrasound  
     transducer 318  
 single-element ultrasound transducers  
     321  
 skin 1  
     appendages 8–9  
     dermis 6–7  
     epidermal self-renewal 9–10  
     epidermis 3–6  
     homeostasis 9  
     hypodermis 7  
     thick and thin 2–3  
     tissue layers, organization of 2  
 skin anisotropy 385, 386  
 skin cancer 25, 83–96, 169, 309, 330,  
     332, 353, 374, 414–418  
     fruit fly models of 115–116  
 skin disorder management,  
     microneedles in 247  
 skin functional imaging 387

- skin grafts 110, 122, 147, 157–158, 163, 423
- skin imaging 24, 320, 322, 326, 328, 341–359, 371–400, 411–429, 443, 448
- in clinical practice 387
- skin morphology imaging 387, 399, 400
- skin papillary dermis imaging 372
- skin permeation routes 171–172
- skin permeation, peptides for 190
- skin tissue engineering
- goal 147
- nanofiber fabrication techniques 154–157
- nanostructured materials for 148–154
- skin grafts 157–159
- stem cell application 159–162
- small molecules 40, 116, 169, 191, 215, 294
- Smartphone Apps for wound measurements 22
- SMOinh-resistant BCC 88
- solid microneedles 225
- dip coating 234
- vaccine delivery 235–237
- somatotropin 210
- sonophoresis 276–278, 281–282
- and microneedles 245
- spantide II 187
- spatial compound imaging 323, 324
- spatial laser speckle contrast 445
- speckle analysis 459–460
- spectral-/Fourier-domain FF-OCT 376
- specular scattering 311–312
- spherical concave transducer 273
- spherical nucleic acids 191
- spherical Radon transform 413
- spherically focused high-frequency ultrasound transducer 323
- spinous keratinocytes 5
- spring-powered needle-free liquid jet injectors 203
- squamous cell carcinoma (SCC) 83, 85, 87–89
- static scattering 446
- stratum basale 4–7, 9, 124, 170
- stem cell application 159–162
- steroids 47, 49, 67, 70, 72, 73, 281
- stratum corneum (SC) 6, 170
- bricks and mortar barrier model of 10, 12
- primary role 170–171
- skin permeation routes 171–172
- water barrier function 10–11
- stratum granulosum 4, 6, 10, 11, 126, 171
- stratum lucidum 3–4, 6
- stratum spinosum 4–5, 117, 171
- sub millimetre spatial resolution 371
- sub-epidermal low echogenic band 333
- sub-epidermal non-echogenic band 350
- subacute cutaneous lupus erythematosus (SCLE) 47–48
- Sumavel DosePro<sup>®</sup> 211
- superficial basal cell carcinoma 85, 331
- superficial dermal burns (SDBs) 424
- superficial spreading melanoma (SSM) 93
- surface gradient concept 344
- surfactants 180–181
- Sus scrofa* domesticus 128
- synergic grafts 157
- synthetic polymers, for skin tissue engineering 152–153
- PLA, PGA, polyurethane homopolymers 152–153
- PLGA co-polymers and blenders 153
- systemic inflammatory response syndrome (SIRS) 424
- systemic scleroderma 43
- t**
- Talaporfin sodium 425
- tap water iontophoresis 292
- Tappy Tok Tok<sup>®</sup> MN 302
- terpenes 179–180, 300
- terpenoids 179–180

- therapeutic drug monitoring (TDM) 237–238
- thermal effects of ultrasound 275
- three-axis surface gradient systems 344
- three-dimensional (3D) ultrasound microscopy 323
- three-dimensional reconstructed human skin models 109–110
- organoids 112
- reconstituted human dermis models 111
- reconstituted human epidermis models 110–111
- reconstituted skin equivalent model 111–112
- thromboxane A2 17
- thymic stromal-derived lymphopoietin (TSLP) 42
- time-domain (TD) optical coherence tomography (OCT)
- conventional 373–374
- high-definition (HD)-OCT 374–375
- tissue transglutaminase (tTG) 71
- TNF- $\alpha$  inhibitors 39–40, 88
- tolterodine tartrate (TT) 301
- tomographic flow imaging 458–459
- transcutaneous immunisation 283
- TransCyte 159
- transdermal drug delivery
- biodegradable synthetic polymers 185
- lipid based nanoparticles 184–185
- microneedles for 223
- transdermal periodic iontotherapeutic system (TPIS) 300
- transducers and instrumentation 272
- transepidermal water loss (TEWL) measurement 239–240
- transforming growth factor beta 1 (TGF $\beta$ 1) 16
- transit amplifying (TA) cells 159
- transmit and receive delay-and-sum beamforming 326
- transverse magnetization 344
- transverse magnetization decay 343
- triamcinolone acetonide 213–214
- triggered nanodroplets 429
- triptans 211
- trypan blue 240
- tumor environment analysis
- angiogenesis 418–420
- blood flow velocity 421
- metabolic rate of oxygen 421
- oxygen saturation 420–421
- two-dimensional cell culture models 109
- TX/RX switch 327
- U**
- Ultra-Broadband Raster-Scan Optoacoustic Mesoscopy (UB-RSOM) system 422, 423
- ultrasonic palpation method 328
- ultrasonic transducer 313–320, 412–414
- ultrasound 309, 310
- acoustic cavitation 275–276
- acoustic waves 271–272
- beam focusing 326
- bioeffects 271
- mechanism of action 276
- physics of 309–313
- propagation 274
- thermal effects 275
- transducers and instrumentation 272–274
- waves 310–311
- ultrasound enhanced transdermal drug delivery
- co-application of ultrasound and drug 278–279
- drug dosage medium 279–280
- drug formulations 280–282
- immunisation 283–284
- safety concerns 282
- ultrasound pre-treatment 277–278
- ultrasound imaging systems 309, 312
- of inflammatory and infectious skin diseases 332–334
- other skin applications 334
- skin cancer 330–332

- ultrasound imaging systems (*contd.*)
    - with array ultrasound transducers 326–330
    - with single-element ultrasound transducers 321–326
  - ultrasound refraction and reflection 311
  - ultrasound transducer
    - array 318
    - backing layer 317
    - matching layer 317
    - piezoelectric material 314–316
    - single-element piston ultrasound transducer 318
  - unfocused ultrasound transducer 318
  - ureas 177–178
- V**
- vaccines 206–208, 235–237
  - vein pattern recognition 392
  - vertical wide field skin imaging 372
  - vismodegib 84
    - BCC treatment 88
  - visual analog scale (VAS) score 242, 247
  - volumetric melanoma imaging 416
  - voxel encoding constraint 344
  - voxel size 343, 346, 350, 352, 375
- W**
- water–macromolecular interactions 353, 359
  - water barrier function 1, 4, 6, 10–11
  - water states in reconstructed skin 358
  - Western blot analysis
    - paraneoplastic pemphigus 67
  - wet etching 233
  - whole-body gradient systems 344
  - “wide bore” horizontal magnets 351
  - wound healing 15
    - ex vivo* models of cutaneous 107–108
  - confocal microscopy 24–27
  - cutaneous
    - C. elegans* use 113
    - D. melanogaster* 114–115
    - using *D. rerio* 117
    - murine models 120
    - rabbit models of 125
  - diffuse near-infrared spectroscopy 23
  - granulation tissue cell formation 19–20
  - growth factors 17
  - haemostasis and inflammation 15–18
  - hyperspectral imaging 22–23
  - macroscopic digital imaging for wound size 22
  - multiphoton imaging approach 25
  - normal process 19
  - Raman vibrational spectroscopy 23–24
  - re-epithelialization 18–19
  - scar tissue formation 20–21
  - SHG imaging technique 25
  - tissue histology 21–22
- X**
- X-box binding protein 1(*XBPI*) 50
  - xenogenic grafts 157
- Z**
- Z/W plasty 21
  - zebrafish
    - advantages as research model 116
    - drug development 117–118
    - genodermatoses 118
    - pigment pattern 117
    - pigmentation and melanoma study 117
    - skin anatomy and physiology 116, 117
  - Zeneo<sup>®</sup> 212
  - ZomaJet 2 vision 210
  - zwitterionic surfactant 180–181